FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the financial year ended May 31, 2003

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

[Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.]

Form 20-F [ ] Form 40-F [X]

[Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also
thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.

Yes [ ] No [X]

[If "Yes" is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: March 3, 2004

By: "Shane Ellis"

Shane Ellis
Vice President,Legal Affairs
Corporate Secretary

Index for the 6-K filing

.
.
.

Exhibit 99.1

CONTACTS:

<TABLE>
<S> <C> <C>
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS INC. PUBLISHES PRECLINCAL RESULTS DESCRIBING NC 381, A LUNG CANCER ANTI-TUMOR AGENT

- Novel derivative of an anti-fungal drug with anti-tumor properties--

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, DECEMBER 1, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of investigations aimed at characterizing a clotrimazole (CLT) analogue, NC 381. CLT is an anti-fungal drug that has demonstrated anti-cancer activity but its potential is limited by the presence of high liver toxicity. The goal of the study was to develop a variation or analogue of CLT that maintained the anti-cancer activity without the toxic side effects. The results appear in an article entitled, "NC 381, A Novel Anti-cancer Agent, Arrests the Cell Cycle in G0-G1 and Inhibits Lung Tumor Cell Growth In Vitro and In Vivo" in a November electronic version of the Journal of Pharmacology and Experimental Therapeutics. The article will also be published in print in an upcoming issue of the journal.

The article explained that when a chemical component of CLT responsible for toxicity was removed in designing the analogue NC 381, the new drug inhibited the growth of cancer cells in vitro by a mechanism of action that was similar to CLT. Therefore, this new drug appears to be a safer agent that maintains anti-cancer activity.

Also, the clinical applicability of NC 381 was evaluated in a mouse model of human lung cancer. In this model, NC 381 treatment significantly inhibited tumor growth in vivo, demonstrating the potential of NC 381 for treatment of lung cancer.

(more)

Lorus recently licensed NC 381 and the library of CLT analogs to Cyclacel Limited ("Cyclacel"), a UK-based biopharmaceutical company. Lorus received an upfront payment for the library including NC 381, and assuming all clinical development milestones are achieved by Cyclacel, Lorus will also receive milestone payments that total approximately US $11.6 million for NC 381 and for each of any other compounds developed from the compound library. In addition to these payments, Lorus will receive royalties based on product sales.

"Cyclacel has expertise in the area of drug development represented by anti-cancer agents like NC 381 and the other CLT analogs, and is an excellent partner for Lorus," said Dr. Jim Wright, CEO of Lorus. "This agreement is also consistent with Lorus' focus on progressing its strong preclinical and clinical programs that are now underway and showing very promising results."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations

imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

Exhibit 99.2

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
</TABLE>

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com

LORUS THERAPEUTICS INC. PUBLISHES RESULTS OF SYNTHESIS AND CHARACTERIZATION OF CLOTRIMAZOLE ANALOGUES AS ANTICANCER AGENTS

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, DECEMBER 15, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of experimental studies aimed at synthesizing and optimizing analogues of clotrimazole (CLT), an anti-fungal drug that has demonstrated anticancer activity. These studies were part of a larger project that characterized NC 381, a CLT derivative that was extensively studied as a lead drug candidate. While the class of compounds described in the article are significantly different from the ones to which NC 381 belongs, they all form part of the CLT library of analogues, which provide an opportunity to further advance these analogues with the goal of developing novel anticancer therapeutics. The results appear in an article entitled, "Triaryl-Methane Derivatives as Antiproliferative Agents," published in a peer reviewed December 6th electronic version of the journal Bioorganic and Medicinal Chemistry letters. The article will also be published in print in an upcoming issue of the journal.

"These studies present promising results which we believe demonstrate that in addition to NC 381, there are a number of other derivatives of CLT in the library that are potential drug candidates. On September 24, 2003 Lorus announced an agreement to out-license NC 381 and the library of CLT analogs." said Dr. Jim Wright, CEO of Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Exhibit 99.3

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
</TABLE>

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com

LORUS ANNOUNCES INITIATION OF PHASE II CLINICAL PROGRAM FOR GTI-2501 WITH DOCETAXEL IN HORMONE REFRACTORY PROSTATE CANCER

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, DECEMBER 23, 2003 - Lorus Therapeutics announced today that the clinical study for GTI-2501for the treatment of hormone refractory prostate cancer has been initiated at the Toronto Sunnybrook Regional Cancer Centre. GTI-2501 will be administered in combination with docetaxel. The principal investigator for this study is Dr. Scott Berry, and the co-investigator is Dr. Laurence Klotz. Both clinicians are considered to be leaders in prostate cancer research.

This collaboration between a leading Ontario research centre and an Ontario-based innovative biopharmaceutical company is consistent with provincial and federal policy to encourage novel clinical development in Canada. This marks the first clinical trial of GTI-2501 in Canada, following the successful conclusion of a Phase I clinical trial this year in the US.

GTI-2501 is an antisense drug that specifically targets the R1 component of ribonucleotide reductase, which is required for DNA synthesis and cell division. GTI-2501 has also shown marked antitumor activity in a wide variety of preclinical cancer models, including prostate cancer.

This clinical trial will investigate the safety and efficacy of GTI-2501 in combination with docetaxel, an active chemotherapy in hormone refractory prostate cancer.

According to the Canadian Cancer Society and National Cancer Institute of Canada statistics, prostate cancer is second only to lung cancer in the number of deaths among men in Canada, about 4,300 deaths per year, and is the most prevalent cancer in men. Once advanced prostate cancer stops responding to hormonal therapies, treatment options are limited so the development of new treatments is essential.

(more)

"We are very pleased to be expanding our clinical program for GTI-2501 to a major Canadian clinical research institution," said Dr Jim Wright, CEO of Lorus Therapeutics. "Maintaining quality of life is a key concern when treating prostate cancer. Based on preclinical and early human studies with GTI-2501, we believe that it will be well tolerated as a combination chemotherapy with potential for clinical efficacy in this challenging disease."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties,

intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Exhibit 99.4

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
</TABLE>

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com

LORUS THERAPEUTICS ANNOUNCES INTERIM CLINICAL RESULTS OF GTI-2040 IN COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF RENAL CELL CANCER

- Further clinical development plans to proceed -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, JANUARY 12, 2004 - Lorus Therapeutics Inc. ("Lorus") announced today interim results from a recently conducted exploratory Phase II clinical trial of GTI-2040 in patients with advanced, end-stage renal cell cancer in the United States. This trial was a single-arm pilot study examining the safety and efficacy of GTI-2040 used in combination with the anticancer agent capecitabine. To date, data have been collected on 21 patients evaluable for tumor assessment. One patient is still receiving treatment after eight months of therapy with GTI-2040 and capecitabine. Four additional patients will be accrued.

The majority of patients had failed two or more prior therapies before entering the study, exhibited extensive metastases, and were representative of a population with very poor prognostic outcome in renal cell cancer. In the present clinical study, few treatment-related toxicities outside of those already known to occur with the test drugs were observed. Unaudited data analysis showed that more than half of the 21 evaluable patients in this study exhibited disease stabilization, ranging up to eight months. Tumor shrinkages of index tumors compared to baseline measurements were observed in some patients. A full assessment of tumor responses will be completed and a final independent review of results will occur following conclusion of the study.

(more)

Lorus' objective is to further the clinical development of its lead antisense drug, GTI-2040 in renal cell cancer with the intention of progressing the drug into a definitive Phase II/III registration program. The drug would be studied in early stage rather than late stage renal cell cancer in combination with a cytokine, as these are agents commonly used in the first or second-line clinical setting. This decision also reflects recent promising preclinical data, showing positive antitumor efficacy in combination with cytokines like interleukin and interferon. Discussions with leading clinical experts on the design of the investigation are underway, but will likely include a pharmacokinetic and disease response analysis of GTI-2040 in combination with a first-line approved therapy versus first-line therapy alone, in previously untreated, newly diagnosed patients.

"We are encouraged by initial clinical evidence in this single-arm trial of disease stabilizations and tumor shrinkages in a heavily-pretreated and multiple-relapsed population," said Dr. Jim Wright, chief executive officer of Lorus. "Lorus has decided to move development of GTI-2040 to a first or second-line indication in renal cell cancer, rather than end-stage disease. We believe this approach provides the greatest opportunity to demonstrate the anticancer activity of GTI-2040 in renal cell cancer, and the potential to enhance the commercial value of the drug."

Renal cell carcinoma is the most common type of kidney cancer with more than 190,000 cases diagnosed annually across all countries. The majority of patients are over the age of 40. More than 90,000 patients die annually from this disease worldwide. The age-adjusted world incidence in renal cell carcinoma has been increasing steadily at an annual rate of approximately two per cent. Advanced renal cell cancer is typically resistant to chemotherapy, with reported response rates of less than 10 percent. Current treatments include the cytokines interferon, and interleukin-2, however tumor response rates for these agents are low, in the range of 15 per cent.

About GTI-2040

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. It has also been described as a malignant determinant that is

elevated in a wide range of tumors, and through deregulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 showed significant antitumor activity against many different human tumors in preclinical studies. In addition to the clinical trial in renal cell cancer described above, GTI-2040 is currently the subject of a Clinical Trial Agreement with the United States National Cancer Institute (NCI) under which GTI-2040 will be tested in combination chemotherapy in six different clinical trials. Three of these trials have been initiated including treatment of metastatic breast cancer at the University of California, Davis Cancer Center; acute myeloid leukemia at the Ohio State University Medical Center and non-small cell lung cancer at Princess Margaret Hospital in Toronto, Canada. The three remaining clinical trials to be initiated with NCI sponsorship will investigate GTI-2040 in colon cancer, prostate cancer, and a variety of solid tumors.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Exhibit 99.5

CONTACTS:

<TABLE>
<S> <C> <C>
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Inc. Grace Tse Mansfield Communications Inc. Mansfield Communications
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS INC. TO PRESENT RESULTS OF VIRULIZIN(R) MECHANISM STUDIES AT THE ASCO GASTROINTESITINAL CANCERS SYMPOSIUM

-Latest research into Virulizin(R) as an antitumor agent to be presented -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, JANUARY 22, 2003 - Lorus Therapeutics Inc. ("Lorus") will be attending the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium to be held in San Francisco on January 22-24, 2004. An abstract entitled, "Induction of NK cell and macrophage infiltration into tumors may contribute to antitumor activity of Virulizin(R)," has been accepted for presentation. The abstract will also be published in the meeting proceedings. These studies were conducted as a collaboration between Lorus scientists and researchers at the Calcium Research Laboratory, Department of Medicine, McGill University.

Virulizin(R) has demonstrated antitumor activity against a variety of tumors including pancreatic cancer and melanoma. A significant role for an immune-based mechanism of action has been described in this presentation and an earlier study had shown that macrophages, cells involved in innate immunity, are involved in Virulizin(R)-mediated antitumor activity. This presentation will summarize the latest research with animal models into the antitumor mechanism of action of Virulizin(R).

The present study extends the previous findings and identifies natural killer (NK) cells as participants in Virulizin(R)'s mechanism of action. NK cells constitute another major cellular component of the innate immune system and are essential to early surveillance and removal of cancer cells.

(more)

Virulizin(R) treatment of mice bearing human tumors resulted in increased numbers of both macrophages and NK cells within the implanted tumors. Time course experiments demonstrated that recruitment of these cells to tumors was rapid after initiation of Virulizin(R) treatment, and correlated with early signs of programmed cell death. In mice with NK cell-deficiency, the antitumor activity of Virulizin(R) was greatly reduced. In addition, depletion of macrophages from mice resulted in the loss of the Virulizin(R)-induced increase in NK cells in tumors.

Taken together, these data support a mechanism in which Virulizin(R) induces a rapid and sustained induction of the innate cellular immune system resulting in antitumor activity based on the interplay between macrophages and NK cells.

"The research team at Lorus continues to build upon previous observations and the data being presented are an indication of our deepened understanding of the mechanism by which Virulizin(R) acts as an anticancer agent," said Dr. Jim Wright, chief executive officer of Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual

results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Exhibit 99.6

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
</TABLE>

<TABLE>
<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com
</TABLE>

<TABLE>
<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS ANNOUNCES CLINICAL STUDY TO INVESTIGATE THE COMBINATION OF GTI-2040 AND GEMCITABINE

- Complementary intracellular mechanisms provide opportunity for enhanced effects when used together-

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, FEBRUARY 10, 2004 - Lorus Therapeutics Inc. announced today the initiation of a clinical trial aimed at examining the clinical application of its antisense drug, GTI-2040, in combination with gemcitabine in patients with solid tumors. This study is part of a larger clinical development program sponsored and coordinated by the US National Cancer Institute (NCI) in collaboration with Lorus. Dr. Chris Takamoto, the principal investigator, is an oncology researcher and director of pharmacokinetics at the Institute for Drug Development, Cancer Therapy and Research Center in San Antonio, where the study will be conducted.

GTI-2040 and gemcitabine have complementary intracellular mechanisms of action for blocking DNA synthesis and subsequently inhibiting the growth of tumor cells. This convergence of drug mechanisms of action provides the potential for enhanced or synergistic effects when used in combination.

The study will determine the recommended dose of GTI-2040 when administered with gemcitabine, an established chemotherapeutic agent. In addition, the study will evaluate the plasma pharmacokinetics and pharmacodynamics of each drug and examine cellular biomarkers that may correlate with clinical outcomes. One such biomarker is R2, the gene target of GTI-2040, and an essential component of ribonucleotide reductase, an enzyme required for cell division. The R2 component is elevated in many tumor types, and as such, suppression of R2 by GTI-2040 may serve as a biomarker for clinical response. Finally a number of clinical correlates will be investigated, in particular markers for apoptosis, or programmed cell death, which may represent an additional mechanism by which GTI-2040 selectively kills tumor cells.

(more)

Preclinical research has shown that GTI-2040 has a broad spectrum of anticancer activity across a range of human tumors in mouse xenograft models, and when combined with other chemotherapies has improved antitumor activity with little additional toxicity. Gemcitabine (GEMZAR) is currently approved for the treatment of advanced pancreatic cancer and lung cancer.

"We are excited about the expanded range of clinical applications offered by this drug combination," said Dr. Jim Wright, chief executive officer of Lorus. "Of particular interest is the potential for GTI-2040 to reduce the development and/or the extent of resistance of cancer cells to gemcitabine, an important cause of treatment failure. If demonstrated this would provide new hope for patients with drug-resistant tumors."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual

results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Exhibit 99.7

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
</TABLE>

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com

LORUS THERAPEUTICS PARTICIPATES IN 2ND ANNUAL ANTISENSE AND SIRNA TECHNOLOGIES CONFERENCE IN LONDON, ENGLAND

- CEO Jim Wright invited as a feature presenter on antisense technology -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, FEBRUARY 17, 2004 - Lorus Therapeutics Inc. ("Lorus") announced today that Dr. Jim Wright, chief executive officer of Lorus, will be presenting a comprehensive review of the development of Lorus' GTI-2040 and GTI-2501 antisense drugs today at the 2nd Annual Antisense and siRNA Technologies Conference in London, England.

Highlighting Lorus' antisense program, Dr. Wright's presentation will discuss drug targets and their role in cancer, anti-tumor activity, in vitro and in vivo evidence of antisense mechanism of action, and review the progress Lorus has made in advancing GTI-2040 and GTI-2501 in clinical and preclinical programs.

"Lorus is pleased to present its science in a forum that includes peers in the area of antisense drug development," said Jim Wright, chief executive officer of Lorus. "The conference is an excellent opportunity for an exchange on the latest research in antisense technology."

The conference brings together leading industry experts to track the new developments in antisense and siRNA technologies and examine new clinical trial results and approaches. The event will also endeavour to discuss the medicinal chemistry behind effective therapeutic design, drug delivery, manufacture and purification. As the industry broadens its knowledge of this exciting area, this conference will discuss the strategies and practices in place and ideas for the future, as well as analyze the prospects and commercial potentials for antisense technologies.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or

in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any

forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

Exhibit 99.8

CONTACTS:

<TABLE>
<S> <C> <C>
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
</TABLE>

LORUS ANNOUNCES AMERICAN STOCK EXCHANGE LISTING

TSX: LOR
OTC BB: LORFF

TORONTO - FEBRUARY 18, 2004 - Lorus Therapeutics Inc. ("Lorus") today announced that it has been approved for trading on the American Stock Exchange under the symbol "LRP," subject to the fulfillment of certain conditions. Trading is expected to commence on Monday, February 23, 2004.

"This new listing in the United States will increase our visibility and facilitate the broader participation of American investors in Lorus," said Dr. Jim Wright, CEO of Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

About American Stock Exchange

The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRSSM. In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 124 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.